KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters

Published on : Published by : Chris Frew

KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters Nivesh Mittal, Ph.D., Product Development Scientist, to propel production of ErythroMer™   March 24, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing ErythroMer, a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, today announced the hiring [….]

VerImmune Inc Appoints Oncology Veteran as Interim Chief Business Officer

Published on : Published by : Chris Frew

VerImmune Inc Appoints Oncology Veteran as Interim Chief Business Officer A biotech industry veteran in oncology to lead business development and alliance-building efforts for VerImmune’s proprietary Anti-tumor Immune Redirection (AIR) platform Baltimore, Maryland – Feb 14th, 2020 – VerImmune, Inc., a privately-owned immuno-oncology biotechnology company developing a first-in-class broad-spectrum cancer therapy for solid tumors based on [….]

NexImmune Bolsters Leadership Team Adding Former MedImmune Executive as Chief Financial Officer

Published on : Published by : Chris Frew

NexImmune Bolsters Leadership Team Adding Former MedImmune Executive as Chief Financial Officer GAITHERSBURG, Md., Jan. 09, 2020 (Excerpts below were originally published on GLOBE NEWSWIRE) NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veteran John Trainer, MBA has been appointed as the [….]

NexImmune Appoints Industry Veteran Chief Medical Officer to Executive Team

Published on : Published by : Chris Frew

NexImmune Appoints Industry Veteran Chief Medical Officer to Executive Team GAITHERSBURG, Md., Jan. 09, 2020 (originally published on GLOBE NEWSWIRE) NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veterans Han Myint, MD has been appointed as the Company’s Chief Medical Officer. Additionally, [….]

Emmes Names Lynn Lewis Chief Business Officer

Published on : Published by : Chris Frew

Emmes Names Lynn Lewis Chief Business Officer Monday, November 25, 2019 Emmes today announced that Lynn Lewis has joined the company as chief business officer, a newly created position. Her overall focus is to build deeper relationships with existing clients and to develop new business opportunities, particularly among biotech and pharmaceutical companies. Lewis will be [….]

Todd Chappell Appointed CEO of Rasio Therapeutics

Published on : Published by : Chris Frew

Todd Chappell  Appointed CEO of Rasio Therapeutics Chappell is a 20-year veteran of the biopharma industry with experience running multiple drug development programs from the discovery stage through to clinical trials November 14, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran medtech and [….]

Emergent BioSolutions Welcomes Syed T. Husain as their New Senior Vice President, CDMO Business Unit Head

Published on : Published by : Chris Frew

Emergent BioSolutions Welcomes Syed T. Husain as their New Senior Vice President, CDMO Business Unit Head Mr. Husain joined Emergent in September 2019 and serves as the head of the contract development and manufacturing (CDMO) business unit. He most recently served as chief commercial officer at Alcami Corporation. Prior to that, he was head of [….]

Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board

Published on : Published by : Chris Frew

Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board ROCKVILLE, Md.–(BUSINESS WIRE)– Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School Neurosurgeon-in-Chief and [….]

CRB Welcomes Jacob Greenwood as Director of Business Development

Published on : Published by : Chris Frew

CRB Welcomes Jacob Greenwood as Director of Business Development Rockville, MD – September 3, 2019 – CRB is excited to welcome Jacob Greenwood as Director of Business Development in the Maryland office. Greenwood has twelve years’ experience in the biotechnology field, as well as a background in marketing and sales, technical services, and facility/program management.  [….]